Active Implantable Medical Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices {Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Heart Monitors/Insertable Loop Recorders}, Implantable Neurostimulators {Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others}, Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the Increasing prevalence of chronic diseases such as neurological disorders, cardiovascular disorders, and hearing disability, Increased in product development activities across the globe, and Increased awareness and early diagnosis across the globe.

The active implantable medical devices market was valued at USD 25,360.78 million in 2024, growing at a CAGR of 7.82% during the forecast period from 2025 to 2032 to reach USD 46,281.18 million by 2032. The global active implantable medical devices market is propelled by a convergence of factors shaping the medical device landscape. Firstly, the increasing prevalence of chronic diseases, such as neurological disorders, cardiovascular disorders, and hearing disability, fuels the demand for active implantable medical devices. Additionally, in response to this demand, there has been a surge in product development activities worldwide, with companies investing in innovative solutions to address these complex health issues. Moreover, enhanced awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. This convergence of increasing disease prevalence, innovation in product development, and heightened awareness collectively foster a robust growth trajectory for the active implantable medical device sector during the forecast period from 2025 to 2032.

Active Implantable Medical Devices Market Dynamics:

According to the latest data from the World Health Organization (2024), by 2050, nearly 2.5 billion people will experience hearing loss, with 700 million needing rehabilitation. A significant factor is unsafe listening habits, placing over 1 billion young adults at risk. The majority of severe hearing loss cases 80% occur in low- and middle-income countries. Additionally, hearing loss increases with age, affecting over 25% of individuals over 60. Thus, due to the rise in cases of hearing loss, the demand for advanced and effective solutions like cochlear implants and middle-ear implants is rising rapidly. These devices address hearing impairments by directly stimulating the auditory nerve or enhancing the transmission of sound vibrations, offering patients improved auditory perception and quality of life.

Additionally, Epilepsy, one of the most widespread neurological disorders, affects approximately 50 million people worldwide, according to the World Health Organization (2024), with nearly 80% of cases occurring in low- and middle-income countries. Moreover, over one-third of the global population is affected by neurological conditions, making them a leading cause of illness and disability. Neurological disorders such as Parkinson's disease, epilepsy, and chronic pain are fueling the demand for active implantable devices like deep brain and spinal cord stimulators, which provide targeted nerve modulation.

Moreover, According to the World Heart Federation (2024), globally, approximately 620 million people 1 in 13 were living with heart and circulatory diseases. Of these, 340 million cases are in Asia and Australia, and 100 million are in Europe. Coronary heart disease affected 200 million people, including 110 million men and 80 million women. Additionally, there were 56 million female stroke survivors and 45 million male survivors, while 13 million people lived with congenital heart disease, with many cases potentially undiagnosed. Thus, pacemakers, defibrillators, and ventricular assist devices play a crucial role in managing cardiovascular diseases by regulating heart function and thereby boosting the overall market of active implantable medical devices across the globe.

Furthermore, the Active Implantable Medical Devices (AIMD) market is experiencing rapid growth, fueled by significant advancements in product development, R&D efforts, and regulatory approvals across the globe. Leading companies such as Medtronic, Boston Scientific, and Abbott are spearheading these innovations, bringing new devices to address critical medical conditions, especially in cardiac, neural, and hearing-related applications.

For instance, in December 2023, CARMAT achieved a major milestone with the first implantation of the Aeson(R) total artificial heart in a patient with a cardiac tumor. By January 2024, the company had completed 50 successful implants of this groundbreaking device, which is crucial for patients with end-stage heart failure, offering a new lease on life for those awaiting heart transplants.

Thus, the factors mentioned above are expected to boost the overall market of active implantable medical devices across the globe during the forecast period from 2025 to 2032.

However, the high cost of active implantable devices in developing countries and the increase in product recalls across the globe may hinder the future market of active implantable medical devices across the globe during the forecasted period.

Active Implantable Medical Devices Market Segment Analysis:

Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices {Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Heart Monitors/Insertable Loop Recorders}, Implantable Neurostimulators {Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others}, Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The implantable cardioverter defibrillators category in the active implantable medical devices market is estimated to dominate the market with a market share of 35.21% in 2024. Implantable cardioverter defibrillators (ICDs) are playing a pivotal role in boosting the overall market of active implantable medical devices (AIMDs) by addressing the growing global burden of cardiovascular diseases, particularly life-threatening arrhythmias. ICDs are life-saving devices designed to monitor heart rhythms and deliver electrical shocks to restore normal heartbeats in cases of sudden cardiac arrest (SCA) or ventricular arrhythmias. With the increasing prevalence of conditions such as coronary artery disease, heart failure, and inherited arrhythmogenic disorders, the demand for ICDs has surged. According to the World Heart Federation (2024), around 60 million people globally suffer from atrial fibrillation (AF), a common form of arrhythmia that increases the risk of stroke, heart failure, and blood clots. People with AF are five times more likely to experience a stroke. In 2021, more than 500,000 people in Australia were affected by AF, as reported by the Australian Institute of Health and Welfare. These implantable cardioverter defibrillator devices are critical for preventing sudden cardiac arrest, a leading cause of death worldwide, which underscores their importance in modern cardiology.

Technological advancements in ICDs are also driving their adoption and market expansion. Modern ICDs feature dual- and triple-chamber capabilities, remote monitoring systems, and sophisticated algorithms for detecting and treating arrhythmias with higher precision. These innovations enhance patient safety and improve device efficacy while reducing unnecessary shocks, a key concern in older models. Subcutaneous ICDs (S-ICDs) have emerged as a transformative innovation, offering an entirely extravascular option for patients with limited venous access or a higher risk of infection. The introduction of S-ICDs not only expands the patient pool but also addresses concerns about lead-related complications, making them a preferred choice among certain patient groups. For instance, in October 2023, Medtronic gained FDA approval for the Aurora EV-ICD(TM) MRI SureScan(TM) (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV(TM) MRI SureScan(TM) defibrillators, which treat dangerously fast heart rhythms that can cause sudden cardiac arrest (SCA). The Aurora EV-ICD provides lifesaving defibrillation, anti-tachycardia pacing (ATP), and backup (pause-prevention) pacing therapy with a device that is similar in size, shape, and lifetime to typical transvenous ICDs.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of active implantable medical devices across the globe.

North America is expected to dominate the overall active implantable medical devices market:

Among all regions, North America is estimated to hold the largest share of 40.49% in the global active implantable medical devices market in 2024, growing at a CAGR of 6.64% during the forecast period from 2025 to 2032. This can be attributed to the increasing prevalence of hearing disability, heart-associated disorders, rise in neurodegenerative disorders, among others. Moreover, the increased awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of active implantable medical devices across the region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in November 2023, approximately 6,520 cases of permanent hearing loss were reported in 2021 in the United States. The demand for advanced hearing solutions thus rises, particularly cochlear implants and middle-ear implants, is surging as they offer effective alternatives for individuals with severe to profound hearing loss who cannot benefit from traditional hearing aids thereby boosting the overall market of active implantable medical devices across the region.

Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, coronary heart disease is the most common type of heart disease, with about 1 in 20 adults on average aged 20 and above suffering from coronary heart disease in the United States. Active implantable devices, such as implantable cardioverter defibrillators (ICDs), pacemakers, and cardiac resynchronization therapy (CRT) devices, are critical in managing these conditions. The high prevalence of CHD in North America, attributed to sedentary lifestyles, unhealthy diets, and aging populations, has created a significant patient pool requiring these life-saving devices.

Furthermore, various key product approvals in the region are some of the other factors that are influencing the positive growth of the market in the United States. For instance, in February 2024, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) approved the WaveWriter(TM) SCS Systems for the treatment of chronic low back and leg pain.

Thus, the above-mentioned factors are expected to escalate the market of active implantable medical devices in the region.

Active Implantable Medical Devices Market Key Players:

Some of the key market players operating in the active implantable medical devices market include Medtronic plc., Johnson and Johnson Services, Inc., Abbott, Boston Scientific Corporation, LivaNova PLC., Axonics, Inc., Aleva Neurotherapeutics, Sonova Holding AG, Bioventus Inc., CARMAT, Jarvik Heart Inc., BIOTRONIK SE & Co. KG, MicroTransponder Inc., MED-EL Medical Electronics, NeuroPace, Inc., NEVRO CORP., Shree Pacetronix, Cochlear Ltd., Berlin Heart, Blackrock Neurotech, and others.

Recent Developmental Activities in the Active Implantable Medical Devices Market:

• In July 2023, Abbott introduced the AVEIR(TM) dual chamber leadless pacemaker, the first of its kind to treat arrhythmias in both the right atrium and ventricle, greatly expanding access to this technology for U.S. patients.
• In December 2022, Abbott launched the Eterna(TM) spinal cord stimulation system, the smallest implantable rechargeable spinal cord stimulator. It incorporates Abbott's low-dose BurstDR(TM) stimulation, offering better pain management outcomes and setting a new standard in chronic pain treatment.
• In November 2022, Cochlear received FDA approval for its Nucleus(R) 8 Sound Processor, the smallest and lightest behind-the-ear processor on the market, incorporating Bluetooth LE Audio technology. This innovation improves connectivity and usability for patients with hearing loss.

Key Takeaways From the Active Implantable Medical Devices Market Report Study

• Market size analysis for current active implantable medical devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the active implantable medical devices market.
• Various opportunities available for the other competitors in the active implantable medical devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current active implantable medical devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for active implantable medical devices market growth in the coming future?

Target Audience Who Can be Benefited From This Active Implantable Medical Devices Market Report Study

• Active implantable medical device product providers
• Research organizations and consulting companies
• Active implantable medical devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in active implantable medical devices
• Various end-users who want to know more about the active implantable medical devices market and the latest technological developments in the active implantable medical devices market.

Frequently Asked Questions for the Active Implantable Medical Devices Market:

1. What are active implantable medical devices?

• Active implantable medical devices are advanced medical devices designed for implantation within the human body. These devices incorporate electronic components that interface with the body's physiological systems to effectively monitor & regulate biological functions.

2. What is the market for active implantable medical devices?

• The active implantable medical devices market was valued at USD 25,360.78 million in 2024, growing at a CAGR of 7.82% during the forecast period from 2025 to 2032 to reach USD 46,281.18 million by 2032.

3. What are the drivers for the global active implantable medical devices market?

• The global active implantable medical devices market is propelled by a convergence of factors shaping the medical device landscape. Firstly, the increasing prevalence of chronic diseases, such as neurological disorders, cardiovascular disorders, and hearing disability, fuels the demand for active implantable medical devices. Additionally, in response to this demand, there has been a surge in product development activities worldwide, with companies investing in innovative solutions to address these complex health issues. Moreover, enhanced awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. This convergence of increasing disease prevalence, innovation in product development, and heightened awareness collectively foster a robust growth trajectory for the active implantable medical device sector during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global active implantable medical devices market?

• Some of the key market players operating in the active implantable medical devices are Medtronic plc., Johnson and Johnson Services, Inc., Abbott, Boston Scientific Corporation, LivaNova PLC., Axonics, Inc., Aleva Neurotherapeutics, Sonova Holding AG, Bioventus Inc., CARMAT, Jarvik Heart Inc., BIOTRONIK SE & Co. KG, MicroTransponder Inc., MED-EL Medical Electronics, NeuroPace, Inc., NEVRO CORP., Shree Pacetronix, Cochlear Ltd., Berlin Heart, Blackrock Neurotech, and others.

5. Which region has the highest share in the global active implantable medical devices market?

• North America region is anticipated to dominate the overall active implantable medical devices market due to the increasing prevalence of hearing disability, heart-associated disorders, and rise in neurodegenerative disorders, among others. Moreover, the increased awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of active implantable medical devices across the region.